Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial.

Sebastian Bauer Robin L Jones Jean Yves Blay André B P van Kuilenburg Suzanne George Patrick Schöffski Margaret von MehrenJohn R ZalcbergYoon-Koo Kang Albiruni Abdul Razak Jonathan C Trent Steven Attia Axel Le Cesne Ying SuJulie MeadeTao WangMatthew L ShermanRodrigo Ruiz-Soto Michael C Heinrich

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)

Ripretinib was not superior to sunitinib in terms of PFS. However, meaningful clinical activity, fewer grade 3/4 treatment-emergent adverse events, and improved tolerability were observed with ripretinib.

Keyphrases

phase iii
open label
phase ii
clinical trial
phase ii study
renal cell carcinoma
metastatic renal cell carcinoma
study protocol
double blind
placebo controlled
randomized controlled trial
chronic myeloid leukemia
squamous cell carcinoma